Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 4, 2015, Pages 396-404

  Funderburg, Nicholas T ^a   Jiang, Ying ^b   Debanne, Sara M ^b   Labbato, Danielle ^b,c,d   Juchnowski, Steven ^c   Ferrari, Brian ^b   Clagett, Brian ^b   Robinson, Janet ^b,c   Lederman, Michael M ^b,c   McComsey, Grace A ^b,c,d  

^a OHIO STATE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

HIV 1; inflammation; monocytes; rosuvastatin; T lymphocytes; tissue factor

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIHYPERTENSIVE AGENT; CD14 ANTIGEN; CD163 ANTIGEN; CD38 ANTIGEN; D DIMER; DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HIGH DENSITY LIPOPROTEIN; HLA DR ANTIGEN; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA; ANTIRETROVIRUS AGENT; FLUOROBENZENE; HYPOCHOLESTEROLEMIC AGENT; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; ANTIVIRAL THERAPY; CARDIOVASCULAR RISK; CAUCASIAN; CD4 CD8 RATIO; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEPATITIS B; HEPATITIS C; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYALGIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS; CHEMISTRY; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; ANTICHOLESTEREMIC AGENTS; ANTIGENS, CD; FEMALE; FLUOROBENZENES; HIV INFECTIONS; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; MONOCYTES; PROGRAMMED CELL DEATH 1 RECEPTOR; PYRIMIDINES; ROSUVASTATIN CALCIUM; SULFONAMIDES; T-LYMPHOCYTES; TREATMENT OUTCOME; VASCULITIS;

EID: 84924459295     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000478     Document Type: Conference Paper

References (50)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695
2. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204-212
3. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203
4. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133-1144
5. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infec Dis. 2010;201:1796-1805
6. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infec Dis. 2011;203: 780-790
7. Brown TT, Tassiopoulos K, Bosch RJ, et al. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010;33:2244-2249
8. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009;49:1119-1127
9. Tabib A, Leroux C, Mornex JF, et al. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-viruspositive patients. Coron Artery Dis. 2000;11:41-46
10. Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci. 2008; 336:402-406
11. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603-1608
12. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirusspecific T-cell responses. AIDS. 2006;20:2275-2283
13. Hsue PY, Giri K, Erickson S, et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation. 2004;109:316-319
14. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-Association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193
15. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735
16. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-1029
17. Crum-Cianflone NF, Weekes J, Bavaro M. Thromboses among HIVinfected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS. 2008;22:771-778
18. Fultz SL, McGinnis KA, Skanderson M, et al. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med. 2004;116:420-423
19. Klein SK, Slim EJ, de Kruif MD, et al. Is chronic HIV infection associated with venous thrombotic disease?. A systematic review. Neth J Med. 2005;63:129-136
20. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-2512
21. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859-870
22. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543
23. Longenecker CT, Funderburg NT, Jiang Y, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med. 2013;14:385-390
24. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 2011;203:452-463
25. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis. 2011;217:207-213
26. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977-987
27. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207
28. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis. 2014;58:588-595
29. Eckard AR, Jiang Y, Debanne SM, et al. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209:1156-1164
30. Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203:756-764
31. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204:1217-1226
32. Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndromes. Blood. 2012;120:4599-4608
33. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006;36:104-107
34. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010;115:161-167
35. Baker JV, Hullsiek KH, Singh A, et al. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS. 2014;28:831-840
36. Rogacev KS, Cremers B, Zawada AM, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol. 2012;60:1512-1520
37. Vittos O, Toana B, Vittos A, et al. Lipoprotein-Associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker. Biomarkers. 2012;17:289-302
38. Brilakis ES, Khera A, Saeed B, et al. Association of lipoproteinassociated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. Clin Chem. 2008; 54:1975-1981
39. Brilakis ES, McConnell JP, Lennon RJ, et al. Association of lipoproteinassociated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137-144
40. Jiao Y, Zhang T, Wang R, et al. Plasma IP-10 is associated with rapid disease progression in early HIV-1 infection. Viral Immunology. 2012;25 (4):333-337
41. Stylianou E, Aukrust P, Bendtzen K, Muller F, Froland SS. Interferons and interferon (IFN)-inducible protein 10 during highly active antiretroviral therapy (HAART)-possible immunosuppressive role of IFNalpha in HIV infection. Clin Exp Immunol. 2000;119(3):479-485
42. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371
43. Dimayuga PC, Chyu KY, Kirzner J, et al. Enhanced neointima formation following arterial injury in immune deficient Rag-1-/- mice is attenuated by adoptive transfer of CD8 T cells. PLoS One. 2011;6:e20214
44. Quan L, Jian Z, Ping Z, et al. Proteinase-Activated receptor-1 mediates allogeneic CD8(+) T cell-induced apoptosis of vascular endothelial cells. Med Oncol. 2009;26:379-385
45. Grivel JC, Ivanova O, Pinegina N, et al. Activation of T lymphocytes in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2011;31: 2929-2937
46. Petrovas C, Price DA, Mattapallil J, et al. SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood. 2007;110: 928-936
47. Methe H, Kim JO, Kofler S, et al. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol. 2005;25:1439-1445
48. Bu DX, Tarrio M, Grabie N, et al. Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. J Clin Invest. 2010;120:1961-1970
49. Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005;112:720-726
50. Tuomisto TT, Lumivuori H, Kansanen E, et al. Simvastatin has an antiinflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc Res. 2008; 78:175-184